Stepping down ICS therapy in COPD
Posted on: 16 Oct 2018In most industrialised countries, approximately 40% of patients diagnosed with COPD are candidates for inhaled corticosteroids (ICS). And yet, prescribing rates can exceed 80%. This means that a lot of patients are being exposed to the risks associated with ICS. It also means that the cost of their care is unnecessarily high.
It is important to know whether and how ICS therapy can be safely stepped down.
Access the PCRS desktop helper ‘Evaluation of appropriateness of inhaled corticosteroid (ICS) therapy in COPD and guidance on ICS withdrawal’.
